Latvija -
latviešu -
Zāļu valsts aģentūra
alpicort 0,4 g/100 ml/0,2 g/100 ml uz ādas lietojams šķīdums
dr. august wolff gmbh & co. kg arzneimittel, germany - skābes salicylicum, prednisolonum - uz ādas lietojams šķīdums - 0,4 g/100 ml/0,2g/100 ml
Latvija -
latviešu -
Zāļu valsts aģentūra
upsarin c 330 mg/200 mg putojošās tabletes
upsa sas, france - skābes acetylsalicylicum, skābes ascorbicum - putojošā tablete - 330 mg/200 mg
Latvija -
latviešu -
Zāļu valsts aģentūra
duofilm 167 mg/ml + 167 mg/ml uz ādas lietojams šķīdums
stada m&d srl, romania - skābes salicylicum, skābes lacticum - uz ādas lietojams šķīdums - 167 mg/ml + 167 mg/ml
Latvija -
latviešu -
Zāļu valsts aģentūra
duofilm 167 mg/ml + 167 mg/ml uz ādas lietojams šķīdums
stada m&d srl, romania - skābes salicylicum, skābes lacticum - uz ādas lietojams šķīdums - 167 mg/ml + 167 mg/ml
Latvija -
latviešu -
Zāļu valsts aģentūra
salicilskābes-rff 20 mg/ml uz ādas lietojams šķīdums
rīgas farmaceitiskā fabrika, a/s, latvia - salicilskābe - uz ādas lietojams šķīdums - 20 mg/ml
Latvija -
latviešu -
Pārtikas un veterinārais dienests, Zemkopības ministrija
otibiovin ausu pilieni, šķīdums
bioveta, a.s., Čehija - salicilskābe,carbethopendecinium bromatum,gentamicīna sulfāts,triamcinolone acetonide - ausu pilieni, šķīdums - kaķi; suņi
Latvija -
latviešu -
Ecolab
sporox surface disinfection hydrogen peroxide (h2o2) wipes
ecolab deutschland gmbh -
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
clopidogrel acino
acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiskie līdzekļi - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogrela besilāts - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiskie līdzekļi - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmenta pacēlums, akūts miokarda infarkts, kopā ar asa, medicīniski ārstēti pacienti saņemt trombolītiskā terapija. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. sīkāku informāciju, lūdzu, skatiet sadaļā 5.